Oncotelic Therapeutics, Inc.
OTLC
$0.04
$0.001.27%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 374.05% | 646.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 374.26% | 643.94% | |||
| Operating Income | -374.26% | -643.94% | |||
| Income Before Tax | 32,569.77% | -629.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 22,559.90% | -629.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -17.91% | -0.59% | |||
| Net Income | 24,001.86% | -476.90% | |||
| EBIT | -374.26% | -643.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 22,796.00% | -457.14% | |||
| Normalized Basic EPS | -106.67% | -400.00% | |||
| EPS Diluted | 22,796.00% | -516.67% | |||
| Normalized Diluted EPS | -106.67% | -475.00% | |||
| Average Basic Shares Outstanding | 3.47% | 4.44% | |||
| Average Diluted Shares Outstanding | 3.47% | -5.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||